News
Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the ...
11h
Stocktwits on MSNAdagene Receives FDA Guidance On Future Clinical Development Of Experimental Cancer Drug: Retail Turns OptimisticAdagene Inc. (ADAG) on Tuesday said that it received directions from the U.S. Food and Drug Administration on further ...
Merck is tackling its looming “Keytruda cliff” with a bold $10 billion acquisition of Verona Pharma. The deal brings Ohtuvayre, a first-in-class COPD drug, into Merck’s portfolio as it looks to ...
Pembrolizumab, an anti-programmed death receptor-1 (PD-1) therapy, is currently approved under the brand name Keytruda ® for other gynecological cancers, including cervical cancer and endometrial ...
BioNTech SE's turn toward oncology treatments has the potential to tap multi-billion-dollar markets in the future. Find out ...
The main patent for Ohtuvayre, the COPD drug at the heart of Verona’s $10 billion sale, expired in 2020. For Merck to make ...
4d
Zacks Investment Research on MSNMerck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?Merck MRK announced a definitive agreement to acquire Verona Pharma VRNA for approximately $10 billion. The deal will add ...
Two Indian nationals were sentenced to 30 months in prison for smuggling counterfeit cancer drugs into the US.
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
Two Indian brothers received 30 months in prison for selling counterfeit drugs to U.S. patients, endangering lives across the country.
Two brothers from India were sentenced to 30 months in prison after they were found guilty of trying to sell counterfeit, ...
A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results